Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Haematological malignancies

1314 - ZUMA-4 preliminary results: phase 1 study of KTE-C19 chimeric antigen receptor T cell therapy in pediatric and adolescent patients (pts) with relapsed/refractory acute lymphoblastic leukemia (R/R ALL)

Date

11 Sep 2017

Session

Haematological malignancies

Topics

Cancers in Adolescents and Young Adults (AYA);  Leukaemia

Presenters

Daniel Lee

Citation

Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373

Authors

D.W. Lee1, A.S. Wayne2, V. Huynh3, R. Handgretinger4, R. Pieters5, G. Michele6, A. Baruchel7, T. Feuchtinger8, Y. Bertrand9, M. Hemiston10, P.A. Brown11, J. Rossi12, Y. Jiang13, L. Navale13, S. Stout14, J. Aycock14, A. Mardiros12, J. Wiezorek14, R. Jain14

Author affiliations

  • 1 Pediatric Stem Cell Transplant Division Of Pediatric Hematology/oncology, University of Virginia, 22908 - Charlottesville/US
  • 2 Children's Center For Cancer And Blood Diseases, Children's Hospital Los Angeles, Usc-norris Comprehensive Cancer Center, Keck School Of Medicine, University of Southern California, Los Angeles/US
  • 3 Department Of Epidemiology And Chao Family Comprehensive Cancer Center/ Hyundai Cancer Institute, Children's Hospital of Orange County, Orange/US
  • 4 Universität Children's Hospital, Eberhard Karls Universität Tübingen, Tübingen/DE
  • 5 Pediatric Oncology, Princess Maxima Center for Pediatric Oncology, Utrecht/NL
  • 6 Hôpital De La Timone, Centre Hospitalier, Universitaire, Marseille Universite, Marseille/FR
  • 7 Pediatric Hematology Hôpital Robert Debré, CHU Paris, Paris/FR
  • 8 Dr. Von Hauner University Children’s Hospital, Ludwig-Maximilians-University Munich, Munich/DE
  • 9 Department Of Pediatric Hematology And Immunology, Centre Hospitalier Universitaire, Lyon/FR
  • 10 Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco/US
  • 11 Pediatric Leukemia Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore/US
  • 12 Translational Sciences, Kite Pharma, Santa Monica/US
  • 13 Biostatistics, Kite Pharma, Santa Monica/US
  • 14 Clinical Development, Kite Pharma, Santa Monica/US
More

Resources

Abstract 1314

Background

ALL is the most common childhood malignancy; up to 20% of pts relapse after initial therapy, and have poor clinical outcomes (Hoffman and Gore. Front Oncol 2014). Promising results were observed with KTE-C19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in B cell malignancies (Locke at al. AACR 2017, #9986). We present preliminary ZUMA-4 phase 1 results.

Methods

Pts aged 2-21 y with R/R ALL and adequate organ function received the planned dose of 1 or 2 × 106 CAR T cells/kg after low-dose conditioning chemotherapy (cyclophosphamide/fludarabine, CyFlu). Pts enrolled after the study’s dose-limiting toxicities (DLTs) portion receive tocilizumab ≤36 h after CAR T cell infusion. Phase 1 primary endpoint is the incidence of DLTs. Secondary endpoints include efficacy and biomarker assessments.

Results

As of Dec 31, 2016, 4 of 5 enrolled pts have been treated; median follow-up, 5.3 mo (1.9-8.6). All pts had ≥2 prior lines of therapy and 1 pt had prior stem cell transplant (SCT). All pts received bridging chemotherapy due to high disease burden (baseline blasts, 41-99%) prior to KTE-C19. KTE-C19 was successfully manufactured in a centralized 6-7 d process across a range of baseline absolute lymphocyte counts (0.5–17.1 × 109/L) and CD4:CD8 ratios (0.1-0.7). KTE-C19 could not be manufactured for 1 pt who progressed with WBC >150,000/µL at apheresis and

Conclusions

KTE-C19 after low-dose CyFlu was tolerable and appears safe for further analysis in pediatric and adolescent pts with R/R ALL. KTE-C19 can induce deep remissions in heavily pre-treated pts with high disease burden. Based on these results, ZUMA-4 continues to enroll (NCT02625480).

Clinical trial identification

NCT02625480

Legal entity responsible for the study

Kite Pharma

Funding

Kite Pharma

Disclosure

D.W. Lee: Honoraria from Juno. A.S. Wayne: Pfizer: Consultancy, Honoraria, advisory board; Kite Pharma: Research Funding, Honoraria, Advisory Board; NIH: Patents; MedImmune: Research Funding; Spectrum Pharmaceuticals: Research Funding; Spectrum: Honoraria, advisory board. R. Handgretinger: Patents and Royalties: Milteny Biotech. J. Rossi, Y. Jiang, L. Navale, S. Stout, J. Aycock: Employment/Stock Ownership: Kite Pharma. A. Mardiros: Employment/Stock Ownership: Kite Pharma; Patents: Mustang Bio. J. Wiezorek: Leadership/Employment/Stock Ownership: Kite Pharma. R. Jain: Patent/Employment/Stock Ownership: Kite Pharma. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.